• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于用高活性钇-90对DOTA肽进行放射性标记的反应条件的优化。

Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.

作者信息

Nardelli Anna, Castaldi Elena, Ortosecco Giovanni, Speranza Antonio, Storto Giovanni, Pace Leonardo, Salvatore Marco

机构信息

Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy.

出版信息

Appl Radiat Isot. 2011 Jan;69(1):52-5. doi: 10.1016/j.apradiso.2010.09.001. Epub 2010 Sep 8.

DOI:10.1016/j.apradiso.2010.09.001
PMID:20869877
Abstract

UNLABELLED

Peptide receptor radionuclide therapy (PRRT) has recently expanded due to radiolabelling of DOTA-peptides, such as the somatostatin analogues [DOTA(0), Tyr(3)]octreotate (DOTATATE). The achievement of high specific activities during procedures has been indicated as the critical factor to consent effective therapy. Several radiochemical factors may negatively impact reaction procedures such as pH, temperature and time of reaction. Our study was undertaken to explore the influence of radiochemical parameters, such as time of incubation, on reaction kinetics during the radiolabelling of DOTATATE with (90)Y.

METHODS

Forty-five radiolabelling procedures were carried out using small volumes of yttrium-90, typically 60-78 μL. At nearly constant pH and temperature two different settings of radiolabelling procedures were implemented, removing the products from the heating water bath approximately after 30 min (group E, early; n=20) and after 39 min (group L, later; n=25). Quality controls were performed by means of both high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC).

RESULTS

Reaction kinetics for (90)Y were found to a provide suitable percentage of incorporation at pH 4.5 for both groups. Reaction temperature was not different between groups E and L. A significant difference was found between the two groups in radiochemical yield, which was 95.6% ± 0.8 for group E and 98.2% ± 1.1 for group L (p<0.0001). The specific activity of the final product was 46.9 MBq/nmol.

CONCLUSION

In order to achieve optimal specific activities, pH, temperature and time of reaction necessitate careful evaluation and setting. A statistically significant difference in labelling yield was found between a set of procedures completed at 39 min as compared to that executed at 30 min, keep the reaction pH and temperature constant.

摘要

未标注

由于DOTA肽(如生长抑素类似物[DOTA(0),Tyr(3)]奥曲肽(DOTATATE))的放射性标记,肽受体放射性核素治疗(PRRT)最近得到了扩展。在操作过程中实现高比活度被认为是实现有效治疗的关键因素。几个放射化学因素可能会对反应过程产生负面影响,如pH值、温度和反应时间。我们的研究旨在探讨放射化学参数(如孵育时间)对用(90)Y标记DOTATATE过程中反应动力学的影响。

方法

使用小体积的钇-90(通常为60-78μL)进行了45次放射性标记操作。在几乎恒定的pH值和温度下,实施了两种不同的放射性标记操作设置,分别在约30分钟后(E组,早期;n=20)和39分钟后(L组,晚期;n=25)从加热水浴中取出产物。通过高效液相色谱(HPLC)和薄层色谱(TLC)进行质量控制。

结果

发现(90)Y的反应动力学在pH 4.5时为两组提供了合适的掺入百分比。E组和L组之间的反应温度没有差异。两组之间在放射化学产率上存在显著差异,E组为95.6%±0.8,L组为98.2%±1.1(p<0.0001)。最终产物的比活度为46.9 MBq/nmol。

结论

为了实现最佳比活度,需要仔细评估和设置反应的pH值、温度和时间。在保持反应pH值和温度恒定的情况下,发现一组在39分钟完成的操作与在30分钟完成的操作相比,标记产率存在统计学上的显著差异。

相似文献

1
Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.用于用高活性钇-90对DOTA肽进行放射性标记的反应条件的优化。
Appl Radiat Isot. 2011 Jan;69(1):52-5. doi: 10.1016/j.apradiso.2010.09.001. Epub 2010 Sep 8.
2
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.在高比活度下用90Y、111In和177Lu对DOTA肽进行放射性标记的条件优化。
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. doi: 10.1007/s00259-003-1142-0. Epub 2003 Apr 4.
3
Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC.奥曲肽类似物68Ga DOTA NOC的放射性标记、质量控制及放射化学纯度评估
Appl Radiat Isot. 2008 Aug;66(8):1091-6. doi: 10.1016/j.apradiso.2007.12.001. Epub 2007 Dec 8.
4
Radiolabelling DOTA-peptides with 68Ga.用68Ga对DOTA肽进行放射性标记。
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85. doi: 10.1007/s00259-004-1702-y. Epub 2005 Jan 18.
5
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.两种用铟和钇放射性标记的奥曲肽类似物在大鼠体内的生物分布。
Anticancer Res. 2010 Jun;30(6):2177-84.
6
Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.用¹²⁵I对葡萄糖-Tyr3-奥曲肽进行放射性标记及其在大鼠体内的代谢分析:与放射性标记的DOTA-Tyr3-奥曲肽比较
Anticancer Res. 2007 Nov-Dec;27(6B):3941-6.
7
Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.在可移植大鼠肿瘤模型中,[(90)Y-DOTA(0),Tyr(3)]奥曲肽放射性核素治疗后的肿瘤反应取决于肿瘤大小。
J Nucl Med. 2001 Dec;42(12):1841-6.
8
Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.使用一周时间内铟 - 111和钇 - 90的DOTA标记性能回归情况。
Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1348. doi: 10.1007/s00259-005-1923-8.
9
Preclinical and clinical studies of peptide receptor radionuclide therapy.肽受体放射性核素治疗的临床前和临床研究。
Semin Nucl Med. 2010 May;40(3):209-18. doi: 10.1053/j.semnuclmed.2009.12.001.
10
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.使用标记生长抑素类似物的治疗:111铟-二乙三胺五乙酸-D-苯丙氨酸1-奥曲肽与钇标记的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-奥曲肽吸收剂量的比较。
Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e.

引用本文的文献

1
Therapeutic Strategies in HCC: Radiation Modalities.肝癌的治疗策略:放疗方式
Biomed Res Int. 2016;2016:1295329. doi: 10.1155/2016/1295329. Epub 2016 Aug 3.